Views & Analysis Embracing New Science for new growth There is a quiet force in the biopharmaceutical industry that could have notable implications.
News Dupixent is first FDA-approved drug for rare skin disease The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
